Most Read Articles
5 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
4 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Yesterday
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

08 Sep 2020

Inotuzumab ozogamicin (InO) provides a safe and effective treatment option for patients with relapsed/refractory acute lymphoblastic leukaemia (R/R ALL) with a high disease burden, a recent study has found.

Researchers performed a posthoc analysis of the INO-VATE trial and looked at the efficacy and safety of InO vs standard of care chemotherapy (SC). Disease burden was assessed according to bone marrow blast percentage (BMB) and was categorized as follows: low (BMB <50 percent), moderate (BMB 50–90 percent), and high (BMB >90 percent).

InO performed significantly better than SC across all disease burden groups. The rate of complete remission (CR) or CR with incomplete haematologic recovery was significantly higher in the InO group in the low BMB category (73.6 percent vs 45.8 percent; p=0.0022). The same was true for moderate (74.7 percent vs 26.5 percent; p<0.0001) and high (70.0 percent vs 16.7 percent; p<0.0001) BMB.

Overall survival was likewise improved after InO treatment in the low (hazard ratio, 0.64, 97.5 percent confidence interval [CI], 0.39–1.07; p=0.026), moderate (HR, 0.81, 97.5 percent CI, 0.54–1.20; p=0.1109), and high (HR, 0.60, 97.5 percent CI, 0.32–1.13; p=0.0335) BMB categories. This effect was of borderline significance.

In comparison, InO significantly improved progression-free survival as compared with SC across all disease burden categories.

InO treatment was also relatively safe. Dose reductions and discontinuations due to treatment-emergent adverse events (TEAEs) occurred at a similar rate between the InO and SC arms. In the InO arm, the incidence of grade 5 TEAEs declined with increasing disease burden, while in the SC arm, the relationship between grade 5 TEAEs and disease burden was direct.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
4 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Yesterday
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.